Bank of New York Mellon Corp Lowers Stake in LivaNova PLC (NASDAQ:LIVN)

Bank of New York Mellon Corp cut its position in shares of LivaNova PLC (NASDAQ:LIVN) by 3.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 401,372 shares of the company’s stock after selling 12,360 shares during the quarter. Bank of New York Mellon Corp’s holdings in LivaNova were worth $18,588,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Handelsbanken Fonder AB grew its holdings in shares of LivaNova by 12.1% during the fourth quarter. Handelsbanken Fonder AB now owns 17,637 shares of the company’s stock worth $817,000 after buying an additional 1,900 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of LivaNova by 122.8% during the fourth quarter. New York State Common Retirement Fund now owns 37,557 shares of the company’s stock worth $1,739,000 after buying an additional 20,699 shares in the last quarter. Paradice Investment Management LLC boosted its position in shares of LivaNova by 15.3% in the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company’s stock worth $22,545,000 after acquiring an additional 64,680 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of LivaNova by 2.6% in the fourth quarter. Principal Financial Group Inc. now owns 175,878 shares of the company’s stock worth $8,145,000 after acquiring an additional 4,476 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after acquiring an additional 899 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Trading Up 5.5 %

Shares of LIVN stock opened at $39.06 on Wednesday. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 93.00 and a beta of 1.10. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $36.85 and a fifty-two week high of $64.47. The firm’s 50 day moving average price is $46.47 and its two-hundred day moving average price is $49.25.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Barclays decreased their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Stifel Nicolaus decreased their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC decreased their target price on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.